Literature DB >> 8617508

Genetic and physical mapping at the limb-girdle muscular dystrophy locus (LGMD2B) on chromosome 2p.

R Bashir1, S Keers, T Strachan, R Passos-Bueno, M Zatz, J Weissenbach, D Le Paslier, M Meisler, K Bushby.   

Abstract

The limb-girdle muscular dystrophies (LGMD) are a genetically heterogeneous group of disorders, different forms of which have been mapped to at least six distinct genetic loci. We have mapped an autosomal recessive form of LGMD (LGMD2B) to chromosome 2p13. Two other conditions have been shown to map to this region or to the homologous region in mouse: a gene for a form of autosomal recessive distal muscular dystrophy, Miyoshi myopathy, shows linkage to the same markers on chromosome 2p as LGMD2B, and an autosomal recessive mouse mutation mnd2, in which there is rapidly progressive paralysis and muscle atrophy, has been mapped to mouse chromosome 6 to a region showing conserved synteny with human chromosome 2p12-p13. We have assembled a 6-cM YAC contig spanning the LGMD2B locus and have mapped seven genes and 13 anonymous polymorphic microsatellites to it. Using haplotype analysis in the linked families, we have narrowed our region of interest to a 0-cM interval between D2S2113 and D2S2112/D2S145, which does not overlap with the critical region for mnd2 in mouse. Use of these most closely linked markers will help to determine the relationship between LGMD2B and Miyoshi myopathy. YACs selected from our contig will be the starting point for the cloning of the LGMD2B gene and thereby establish the biological basis for this form of muscular dystrophy and its relationship with the other limb-girdle muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617508     DOI: 10.1006/geno.1996.0157

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  8 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

2.  A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families.

Authors:  P Dinçer; Z Akçören; E Demir; I Richard; O Sancak; G Kale; S Ozme; A Karaduman; E Tan; J A Urtizberea; J S Beckmann; H Topaloğlu
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

3.  Novel diagnostic features of dysferlinopathies.

Authors:  Xiomara Q Rosales; Julie M Gastier-Foster; Sarah Lewis; Malik Vinod; Devon L Thrush; Caroline Astbury; Robert Pyatt; Shalini Reshmi; Zarife Sahenk; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

4.  Autosomal dominant myopathy with proximal weakness and early respiratory muscle involvement maps to chromosome 2q.

Authors:  P Nicolao; F Xiang; L G Gunnarsson; B Giometto; L Edström; M Anvret; Z Zhang
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  Refined mapping of the Welander distal myopathy region on chromosome 2p13 positions the new candidate region telomeric of the DYSF locus.

Authors:  Désirée von Tell; Carl E G Bruder; Louise V B Anderson; Maria Anvret; Gabrielle Ahlberg
Journal:  Neurogenetics       Date:  2003-06-27       Impact factor: 2.660

6.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.

Authors:  Bàrbara Flix; Xavier Suárez-Calvet; Jordi Díaz-Manera; Eva Santos-Nogueira; Renzo Mancuso; Jordi Barquinero; Miquel Navas; Xavier Navarro; Isabel Illa; Eduard Gallardo
Journal:  Stem Cells Dev       Date:  2013-07-26       Impact factor: 3.272

7.  Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes.

Authors:  Esther Fernández-Simón; Cinta Lleixà; Xavier Suarez-Calvet; Jordi Diaz-Manera; Isabel Illa; Eduard Gallardo; Noemí de Luna
Journal:  BMC Musculoskelet Disord       Date:  2020-11-27       Impact factor: 2.362

8.  Screening two mutations in the dysferlin gene by exon capture and sequence analysis: A case report.

Authors:  Xueyan Wang; Yun Yang; Rong Zhou
Journal:  Exp Ther Med       Date:  2016-05-11       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.